Repligen (FRA:RGN) Gross-Profit-to-Asset % : 12.58% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Repligen Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Repligen's annualized Gross Profit for the quarter that ended in Mar. 2025 was €335.8 Mil. Repligen's average Total Assets over the quarter that ended in Mar. 2025 was €2,670.3 Mil. Therefore, Repligen's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 12.58%.

Repligen Gross-Profit-to-Asset % Historical Data

The historical data trend for Repligen's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Gross-Profit-to-Asset % Chart

Repligen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

12.20

18.97

19.22

10.24

9.90

Repligen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															10.83	11.48	10.72	5.65	12.58

Competitive Comparison of Repligen's Gross-Profit-to-Asset %

For the Medical Instruments & Supplies subindustry, Repligen's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Repligen's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Repligen Gross-Profit-to-Asset % Calculation

Repligen's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	262.286	/	( (2596.197	+	2702.331)	/ 2 )
	=	262.286	/	2649.264
	=	9.90 %

Repligen's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	335.8	/	( (2702.331	+	2638.232)	/ 2 )
	=	335.8	/	2670.2815
	=	12.58 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Repligen Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Repligen's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

RGEN:USA RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines